COVID-19 and Pharma’s In-Person Sales Model

Posted by Pratap Khedkar on Mon, Mar 16, 2020

Daniel Brox co-authored this post with Pratap Khedkar.

Access COVID-19 resources

As the world continues to monitor the spread of COVID-19, industries of all kinds have little choice but to change on the spot: Educational institutions are quickly transitioning their lessons online and dine-in restaurants are joining the delivery service industry. As measures like lockdowns and social distancing continue to be enforced amid the public health crisis, pharma needs to figure out what that means for the traditional rep-centric model. Putting a stop to in-person physician promotions would reduce traffic across sites of care (for locations that haven’t already restricted access), thereby lowering the spread of disease to healthcare workers, patients and the reps themselves. It’s the responsible thing to do but enforcing a work-from-home mandate—even temporarily—will be challenging. Big disruptions like these are sure to affect everyday business, but they also hold opportunities to rethink existing approaches and try out new ideas.


>
Read More

Data Alone Can’t Make Health Improvements Happen

Posted by Pratap Khedkar on Thu, Nov 14, 2019

The data changing hands in the new data-driven healthcare partnership between Google and St. Louis-based health system Ascension runs the gamut from patient names and birth dates to lab results and previous hospitalizations. The duo may have its sights set on using this information to personalize care and lower costs, but data privacy alarms are going off everywhere, raising questions about who really owns patient medical records and whether the benefits of sharing patient data outweigh the risks to the patient/consumer.


>
Read More

Technology, Patient Centricity and Disruption Remain Top of Mind for Health System Execs

Posted by Pratap Khedkar on Thu, May 02, 2019

I recently joined more than 4,000 attendees at the Becker's Hospital Review 10th Annual Meeting, held in Chicago in early April, to learn about the most pressing issues in the hospital and health system arena from a deep bench of industry experts. Interesting insights emerged across three of the critical themes that the healthcare industry is contending with, which got me thinking:


>
Read More

What It’ll Take to Follow in Gottlieb’s Footsteps: Protect, Innovate and Scale

Posted by Pratap Khedkar on Thu, Mar 21, 2019

Matt Furlow co-wrote this blog post with Pratap Khedkar.

Scott Gottlieb’s nearly two-year stint as commissioner of the FDA is coming to an end, and with the ink on his resignation letter barely dry, Norman Sharpless was appointed acting head. Gottlieb is a tough act for the former director of the National Cancer Institute to follow, even temporarily. Gottlieb brought welcome change to the agency and excelled across three ideal FDA leader focus areas—to protect, innovate and scale up—when historically, the agency’s focus had been heavily skewed to protect, was slow to innovate and was cautious to scale up.


>
Read More

Our Drug Rebate Prediction Is Coming True: Now Can We Turn Our Attention to the Value of Drugs?

Posted by Pratap Khedkar on Tue, Feb 12, 2019

We predicted last year that prescription drug rebates’ days could be numbered as more healthcare stakeholders clamor for price transparency. Judging by the new rule proposed by Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson, this has now come to pass. The proposal aims to wipe out the behind-the-scenes negotiation tool—which has been linked to a growing discrepancy between a drug’s list and net prices—and instead share the savings directly with Medicare patients. 


>
Read More